Loin d’un « incident exceptionnel », ce qui s’est produit dans le 13ᵉ arrondissement illustre les conséquences du désastre de l'ouverture à la concurrence.
Loin d’un « incident exceptionnel », ce qui s’est produit dans le 13ᵉ arrondissement illustre les conséquences du désastre de l'ouverture à la concurrence.
I'll revisit this post in a month or so with my thoughts
I'll revisit this post in a month or so with my thoughts
Keeping with our tram theme, a T3a example:
Keeping with our tram theme, a T3a example:
i just want to stay inside all day
i just want to stay inside all day
1️⃣3️⃣Terminology change – Hypertensive Urgency (BP > 180/120 without target organ damage) is now referred to as Severe HTN. No need for parenteral therapy, best to treat in the outpatient setting.
📝What’s in a name (renal, nephro, kidney)? #NephJC
1️⃣3️⃣Terminology change – Hypertensive Urgency (BP > 180/120 without target organ damage) is now referred to as Severe HTN. No need for parenteral therapy, best to treat in the outpatient setting.
📝What’s in a name (renal, nephro, kidney)? #NephJC
Takeaways (1)
Target trial emulation in a high-risk, real-world CKD4+ population (typically excluded from RCTs) suggests:
✅ Survival benefit with continued metformin
✅ No excess CV risk or MALA—despite theoretical concerns
Takeaways (1)
Target trial emulation in a high-risk, real-world CKD4+ population (typically excluded from RCTs) suggests:
✅ Survival benefit with continued metformin
✅ No excess CV risk or MALA—despite theoretical concerns
Short recap: #NephJC
🔹REGENCY trial confirms type 2 anti-CD20 efficacy in active lupus nephritis.
🔹Obinutuzumab + standard therapy improved renal response vs. placebo, aligning with NOBILITY trial findings
Short recap: #NephJC
🔹REGENCY trial confirms type 2 anti-CD20 efficacy in active lupus nephritis.
🔹Obinutuzumab + standard therapy improved renal response vs. placebo, aligning with NOBILITY trial findings
A reduction in proteinuria has now been established as a reliable surrogate endpoint for long-term renal outcomes in pts with IgAN
Can we all agree that treatments that ⬇️ proteinuria are generally associated with a slower rate of eGFR decline? @hswapnil.medsky.social
A reduction in proteinuria has now been established as a reliable surrogate endpoint for long-term renal outcomes in pts with IgAN
Can we all agree that treatments that ⬇️ proteinuria are generally associated with a slower rate of eGFR decline? @hswapnil.medsky.social
In your practice:
What is the “best” eGFR? Why is it important? How should it be measured?
Do you regularly measure eGFRcys and calculate the eGFRdiff? #NephJC
In your practice:
What is the “best” eGFR? Why is it important? How should it be measured?
Do you regularly measure eGFRcys and calculate the eGFRdiff? #NephJC
@pierrehaski.bsky.social @mediapart.fr @comitediderot.bsky.social
@pierrehaski.bsky.social @mediapart.fr @comitediderot.bsky.social